Resolving intraluminal drug and formulation behavior: Gastrointestinal concentration profiling in humans

Bergman, 2007, Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors, Int. J. Pharm., 341, 134, 10.1016/j.ijpharm.2007.04.002 Bevernage, 2013, Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues, Int. J. Pharm., 453, 25, 10.1016/j.ijpharm.2012.11.026 Bønløkke, 1997, A new approach for direct in vivo dissolution studies of poorly soluble drugs, Pharm. Res., 14, 1490, 10.1023/A:1012149511768 Bønløkke, 1999, A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans, Eur. J. Pharm. Sci., 8, 19, 10.1016/S0928-0987(98)00055-4 Bønløkke, 2001, Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans, Eur. J. Pharm. Sci., 12, 239, 10.1016/S0928-0987(00)00138-X Brouwers, J., Augustijns, P., 2011. Biorelevant evaluation of supersaturation and precipitation inhibition: do we understand the gastrointestinal environment? In: Bulletin Technique Gattefossé. Presented at the Journées Galéniques, Saint-Rémy de Provence, France, pp. 71–82. Brouwers, 2005, Determination of intraluminal theophylline concentrations after oral intake of an immediate- and a slow-release dosage form, J. Pharm. Pharmacol., 57, 987, 10.1211/0022357056631 Brouwers, 2006, Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir, J. Pharm. Sci., 95, 372, 10.1002/jps.20553 Brouwers, 2007, Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state, Pharm. Res., 24, 1862, 10.1007/s11095-007-9307-3 Brouwers, 2007, In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation, Int. J. Pharm., 336, 302, 10.1016/j.ijpharm.2006.12.011 Brouwers, 2011, Food-dependent disintegration of immediate release fosamprenavir tablets: in vitro evaluation using magnetic resonance imaging and a dynamic gastrointestinal system, Eur. J. Pharm. Biopharm., 77, 313, 10.1016/j.ejpb.2010.10.009 Casey, 1976, Method for monitoring hard gelatin capsule disintegration times in humans using external scintigraphy, J. Pharm. Sci., 65, 1412, 10.1002/jps.2600650941 Corá, 2011, Biomagnetic methods: technologies applied to pharmaceutical research, Pharm. Res., 28, 438, 10.1007/s11095-010-0285-5 Perez de la Cruz, 2006, Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum, J. Pharm. Pharmacol., 58, 1079, 10.1211/jpp.58.8.0009 Go, 1970, Simultaneous measurements of total pancreatic, biliary, and gastric outputs in man using a perfusion technique, Gastroenterology, 58, 321, 10.1016/S0016-5085(70)80032-4 Holmstock, 2013, Exploring food effects on indinavir absorption with human intestinal fluids in the mouse intestine, Eur. J. Pharm. Sci., 49, 27, 10.1016/j.ejps.2013.01.012 Jobin, 1985, Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum, Br. J. Clin. Pharmacol., 19, 97S, 10.1111/j.1365-2125.1985.tb02749.x Kalantzi, 2006, Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies, Pharm. Res., 23, 165, 10.1007/s11095-005-8476-1 Knutson, 1989, A new technique for segmental jejunal perfusion in man, Am. J. Gastroenterol., 84, 1278 Knutson, 2009, Increased understanding of intestinal drug permeability determined by the LOC-I-GUT approach using multislice computed tomography, Mol. Pharm., 6, 2, 10.1021/mp800145r Kostewicz, 2004, Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine, J Pharm Pharmacol, 56, 43, 10.1211/0022357022511 Kostewicz, E.S., Aarons, L., Bergstrand, M., Bolger, M.B., Galetin, A., Hatley, O., Jamei, M., Lloyd, R., Pepin, X., Rostami, A., Sjögren, E., Tannergren, C., Turner, D.B., Wagner, C., Weitschies, W., Dressman, J., 2013a. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci, 57, 300–321. Kostewicz, E.S., Abrahamsson, B., Brewster, M., Brouwers, J., Butler, J., Carlert, S., Dickinson, P.A., Dressman, J., Holm, R., Klein, S., Mann, J., McAllister, M., Minekus, M., Muenster, U., Müllertz, A., Verwei, M., Vertzoni, M., Weitschies, W., Augustijns, P., 2013b. In vitro models for the prediction of in vivo performance of oral dosage forms. Eur. J. Pharm. Sci., 57, 324–366. Koziolek, 2013, Simulating the postprandial stomach: physiological considerations for dissolution and release testing, Mol. Pharm., 10, 1610, 10.1021/mp300604u Lennernäs, 1998, Human intestinal permeability, J. Pharm. Sci., 87, 403, 10.1021/js970332a Lennernäs, H., Aarons, L., Augustijns, P., Beato, S., Bolger, M., Box, K., Brewster, M., Butler, J., Dressman, J., Holm, R., Julia Frank, K., Kendall, R., Langguth, P., Sydor, J., Lindahl, A., McAllister, M., Muenster, U., Müllertz, A., Ojala, K., Pepin, X., Reppas, C., Rostami-Hodjegan, A., Verwei, M., Weitschies, W., Wilson, C., Karlsson, C., Abrahamsson, B., 2013. Oral biopharmaceutics tools – time for a new initiative – an introduction to the IMI project OrBiTo. Eur. J. Pharm. Sci., 57, 292–299. Longstreth, 1975, The gastric response to a transpyloric duodenal tube, Gut, 16, 777, 10.1136/gut.16.10.777 McAllister, 2010, Dynamic dissolution: a step closer to predictive dissolution testing?, Mol. Pharm., 7, 1374, 10.1021/mp1001203 Näslund, 2000, Gastric emptying: comparison of scintigraphic, polyethylene glycol dilution, and paracetamol tracer assessment techniques, Scand. J. Gastroenterol., 35, 375, 10.1080/003655200750023930 Petri, 2003, Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo, Drug Metab. Dispos., 31, 805, 10.1124/dmd.31.6.805 Psachoulias, 2011, Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults, Pharm. Res., 28, 3145, 10.1007/s11095-011-0506-6 Psachoulias, 2012, An in vitro methodology for forecasting luminal concentrations and precipitation of highly permeable lipophilic weak bases in the fasted upper small intestine, Pharm. Res., 29, 3486, 10.1007/s11095-012-0844-z Read, 1983, Effect of gastrointestinal intubation on the passage of a solid meal through the stomach and small intestine in humans, Gastroenterology, 84, 1568, 10.1016/0016-5085(83)90382-7 Rees, 1979, Simultaneous measurement of antroduodenal motility, gastric emptying, and duodenogastric reflux in man, Gut, 20, 963, 10.1136/gut.20.11.963 Schiller, 2005, Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging, Aliment Pharmacol. Ther., 22, 971, 10.1111/j.1365-2036.2005.02683.x Tannergren, 2003, The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique, Br. J. Clin. Pharmacol., 55, 182, 10.1046/j.1365-2125.2003.01722.x Vertzoni, 2012, Luminal lipid phases after administration of a triglyceride solution of danazol in the fed state and their contribution to the flux of danazol across caco-2 cell monolayers, Mol. Pharm., 9, 1189, 10.1021/mp200479f Walravens, 2011, Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations, Clin. Pharmacokinet., 50, 725, 10.2165/11592630-000000000-00000 Weitschies, 2011, In vivo imaging of drug delivery systems in the gastrointestinal tract, Int. J. Pharm., 417, 216, 10.1016/j.ijpharm.2011.07.031 Weitschies, 2010, Magnetic marker monitoring: high resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract, Eur. J. Pharm. Biopharm., 74, 93, 10.1016/j.ejpb.2009.07.007 Wilding, 2001, The role of gamma-scintigraphy in oral drug delivery, Adv. Drug Deliv. Rev., 46, 103, 10.1016/S0169-409X(00)00135-6 Wuyts, 2013, Solubility profiling of HIV protease inhibitors in human intestinal fluids, J. Pharm. Sci., 102, 3800, 10.1002/jps.23698